Shots:

• The P-III JUPITER-06 trial evaluates toripalimab + CT vs PBO + CT in a ratio (1:1) in 514 treatment-naive patients with advanced or metastatic ESCC
• The study met its co-primary 1EPs i.e.- improvements in PFS & OS compared to CT alone. At a prespecified interim analysis on Mar 22- 2021 @median follow-up of 7.4 &7.3mos.; m-OS (17.0 vs 11.0mos.); OS rates @1yrs. (66.0% vs 43.7%); grade ≥3 AEs (73.2% vs 70.0%) & fatal AEs were similar i.e.- 8.2% & no new safety signals were observed
• The companies plan to submit a BLA for toripalimab to the US FDA for the same indication in 2022. In early 2021- Coherus got in-licensed rights to develop and commercialize toripalimab in the US and Canada

  | Ref: Globe Newswire | Image: Coherus